SCHEMBL2233178

SCHEMBL2233178

CCN1CCN(CCCNC(=O)c2ccc(Nc3ncnc4c(C(=O)Nc5c(Cl)c(OC)cc(OC)c5Cl)csc34)nc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 2/20 0.51
DRD2 P14416 2/20 0.43
DRD4 P21917 2/20 0.43
DRD3 P35462 2/20 0.43
IRAK4 Q9NWZ3 2/20 0.40
FGFR3 P22607 7/20 0.40
FGFR1 P11362 3/20 0.40
JAK2 O60674 2/20 0.40
ABL1 P00519 2/20 0.40
INSR P06213 2/20 0.40
LCK P06239 2/20 0.40
FYN P06241 2/20 0.40
YES1 P07947 2/20 0.40
LYN P07948 2/20 0.40
RET P07949 2/20 0.40
MET P08581 2/20 0.40
ROS1 P08922 2/20 0.40
KIT P10721 2/20 0.40
SRC P12931 2/20 0.40
BRAF P15056 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14137180 0.90 MAP3K7 (0.50) MAP3K7DRD2DRD4DRD3IRAK4
SCHEMBL2233029 0.90 MAP3K7 (0.43) MAP3K7FGFR3FGFR1JAK2ABL1
SCHEMBL2232666 0.87 MAP3K7 (0.44) MAP3K7FGFR3FGFR1JAK2ABL1
SCHEMBL2233090 0.86 IRAK4 (0.44) MAP3K7IRAK4FGFR3F2F10
SCHEMBL2232928 0.86 FGFR1 (0.51) MAP3K7FGFR3FGFR1JAK2ABL1
SCHEMBL2234937 0.86 FGFR3 (0.53) FGFR3FGFR1JAK2ABL1INSR
SCHEMBL2232641 0.86 MAP3K7 (0.46) MAP3K7FGFR3FGFR1JAK2ABL1
SCHEMBL14137342 0.83 MAP3K7 (0.42) MAP3K7FGFR3FGFR1JAK2ABL1
SCHEMBL14125238 0.83 IRAK4 (0.42) MAP3K7IRAK4FGFR3BRAFF2
SCHEMBL14125137 0.83 FGFR3 (0.56) FGFR3FGFR1JAK2ABL1INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP disclosed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US disclosed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP disclosed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 MAP3K7 17/4885DRD2 4211/4885DRD4 4606/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 MAP3K7 17/4885DRD2 4211/4885DRD4 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.